CTC
SRPT icon

Central Trust Company’s Sarepta Therapeutics SRPT Stock Holding History

Central Trust Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33
Closed -$565 – 1508
2025
Q2 		$565 Sell
33
-80
-71% -$3.41K ﹤0.01% 1393
2025
Q1 		$7.21K Hold
113
– – ﹤0.01% 1161
2024
Q4 		$13.7K Hold
113
– – ﹤0.01% 1048
2024
Q3 		$14.1K Hold
113
– – ﹤0.01% 1012
2024
Q2 		$17.9K Hold
113
– – ﹤0.01% 957
2024
Q1 		$14.6K Sell
113
-85
-43% -$10.4K ﹤0.01% 1016
2023
Q4 		$19.1K Hold
198
– – ﹤0.01% 959
2023
Q3 		$24K Sell
198
-1,109
-85% -$125K ﹤0.01% 913
2023
Q2 		$150K Sell
1,307
-762
-37% -$98.3K ﹤0.01% 596
2023
Q1 		$285K Buy
2,069
+1,702
+464% +$221K 0.01% 481
2022
Q4 		$47.6K Buy
+367
New +$42.5K ﹤0.01% 778
2018
Q3 		– Sell
-100
Closed -$13K – 1287
2018
Q2 		$13K Buy
+100
New +$9.43K ﹤0.01% 925
2017
Q4 		– Sell
-50
Closed -$2K – 1361
2017
Q3 		$2K Hold
50
– – ﹤0.01% 1169
2017
Q2 		$2K Buy
+50
New +$1.63K ﹤0.01% 1169

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Central Trust Company's SRPT Position: Q3 2025 in Review

Central Trust Company sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 33 shares — an estimated $565 sold.

Central Trust Company first reported a position in SRPT in Q2 2017 and held it in 14 quarters. The position peaked at $285K in Q1 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Central Trust Company reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Central Trust Company sold 33 Sarepta Therapeutics shares in Q3 2025, an estimated $565.
  • Central Trust Company first reported a position in Sarepta Therapeutics in Q2 2017 and held it in 14 quarters.
  • Central Trust Company's Sarepta Therapeutics position peaked at $285K in Q1 2023.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.